ALG2 Gene Glycosylation Disorder Type 1I Genetic Test in UAE – 2800 AED – DHA Licensed Diagnostic Sequencing

Executive Summary & Core Metrics

✓Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing and validated against international genomic databases.
✓Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all Emirates.
✓Clinical Guidance: Telephonic post-test genetic counselling by DHA-licensed professionals integrated with your treating physician’s care plan.
✓Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The ALG2 gene test employs next-generation sequencing to analyze the complete coding region of the ALG2 gene, detecting inherited pathogenic variants responsible for congenital disorder of glycosylation type 1I (CDG‑1I). This rare autosomal recessive metabolic condition disrupts protein glycosylation and affects multiple organ systems. Definitive molecular confirmation guides tailored clinical management, surveillance, and informed family counselling.

Feature	Our Test (ALG2 NGS)	Closest Alternative (Single‑Gene Sanger Sequencing)
Precision	Whole‑gene sequencing with >99% analytical sensitivity for SNVs and small indels	Limited to targeted exons; may miss deep intronic or promoter mutations
Method	Illumina‑based NGS with advanced bioinformatics pipeline	Sanger (capillary) sequencing of selected regions
Turnaround Time	3–4 Weeks	6–8 Weeks (often requires sequential exon testing)
Cost	2800 AED	3500–5000 AED (per gene, partial analysis)

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (Consultant Medical Genetics – DHA Registration ID: 9294403) notes:

“This sequencing assay provides critical molecular evidence to confirm a diagnosis of ALG2‑related glycosylation disorder. However, results must be correlated with the complete clinical phenotype and biochemical markers. A negative finding does not exclude other CDG subtypes or broader metabolic diseases. I strongly advise integrating these results with a comprehensive metabolic workup and formal genetic counselling to ensure accurate interpretation and informed family planning.”

⚠️ Advisory – Medication & Clinical Decision-Making

Do not alter or discontinue any prescribed treatment regimen without consulting your supervising physician. Genetic test results inform long‑term management strategies but do not supersede urgent clinical assessments or immediate therapeutic needs.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Blood transfusion within the past two weeks, active severe systemic infection, or inability to provide informed consent.
Emergency Red Flags: Sudden neurological deterioration, intractable seizures, severe vomiting with dehydration, or loss of consciousness. Seek immediate emergency care without waiting for test results.

Patient FAQ & Clinical Guidance

1. What is the ALG2 gene glycosylation disorder type 1I test?

This is a next-generation sequencing test that analyzes the ALG2 gene to detect inherited mutations causing congenital disorder of glycosylation type 1I (CDG‑1I), a rare metabolic condition affecting multiple body systems. The test provides a precise molecular diagnosis to guide early intervention, surveillance, and genetic counselling for affected families.

2. How is the sample collected for this test?

A certified phlebotomist collects a small blood sample using a DNA‑stabilizing FTA card or a standard EDTA tube. We offer VIP Mobile Phlebotomy across the UAE from 8 AM to 11 PM daily. For infants, a heel‑prick method is available. No fasting is required before collection.

3. How long do results take and what do they mean?

Results are typically ready within 3 to 4 weeks. Reports are classified as positive (pathogenic variant identified), negative (no disease‑causing variant found), or variant of uncertain significance (VUS). A positive result confirms the diagnosis and informs management; a negative result does not rule out all CDG subtypes. A complimentary post‑test genetic counselling session is provided to explain your report in detail.

4. Will insurance cover the cost of this test?

Coverage depends on your individual insurance policy. We offer direct billing verification via WhatsApp at +971 54 548 8731. Please contact us in advance to confirm approval and any applicable co‑pay or deductible requirements.

UAE Regulatory & Data Privacy Adherence

Data Protection & Healthcare Compliance Framework

All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under DHA Facility License No. 1143 and is subject to regular audit by the Dubai Health Authority.

Clinical & Logistical Metadata

Test Name	ALG2 Gene Glycosylation Disorder Type 1I Genetic Test (NGS)
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood (EDTA tube or FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM
Methodology Used	Next-Generation Sequencing (Illumina platform) with targeted bioinformatics analysis
ICD-10-CM Code	E77.8
LOINC Code	94219-5
DHA Facility License & Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE